- Initial diagnosis of a left temporo-occipital glioblastoma on August 17, 2007
- Despite radiotherapy, concomitant administration of Temozolomide as well as additional chemotherapy, clear tumor progression occurred
On August 17, 2007, a left temporo-occipital glioblastoma was diagnosed in a 47-year-old patient and confirmed on August 24, 2007 by a stereotactically sampled biopsy. Despite the adjacent radiotherapy (1.8 Gy/d; total dose 59 Gy) with concomitant administration of Temozolomide (from September 10 – October 26, 2007) followed by three cycles of Temozolomide (November 30 – February 5, 2008) the tumor clearly continued to grow.
Decision for NanoTherm® Therapy
The tumor volume was 23.7 ml on February 19, 2008, and it was decided to treat the patient with a nanoparticle-mediated thermotherapy simultaneously with radiotherapy.
- Instillation of 4.7 ml of NanoTherm® on March 12, 2008
- Postoperative CT on March 13, 2008
- Treatment of patient with alternating magnetic field in the NanoActivator® (March 18 - April 4, 2008: twice a week for 1 hour over a period of 3 weeks, 6 sessions in total)
- CT follow-up scans were performed at 3, 6, 8, 11, and 15 months following completion of the NanoTherm® Therapy
- No tumor progression could be diagnosed
- After 18 months, the status of the patient deteriorated rapidly
- The patient passed in September 2009 due to tumor progression (18 months)
NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.